Litcius/Paper detail

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

Johannes F.E. Mann, Thomas K. Hansen, Thomas Idorn, Lawrence A. Leiter, Steven P. Marso, Peter Rossing, Jochen Seufert, Sayeh Tadayon, Tina Vilsbøll

2020The Lancet Diabetes & Endocrinology150 citationsDOI

Topics & Concepts

SemaglutideMedicinePost-hoc analysisType 2 diabetesRenal functionDiabetes mellitusPost hocMEDLINERandomized controlled trialInternal medicineEndocrinologyLiraglutidePolitical scienceLawDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesDiabetes Management and Research
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials | Litcius